Is your child suffering from seizures and less than 2 years of age?

If so, your child may qualify for the Jazz Piccolo Study!

The Jazz Piccolo Study (Piccolo means “little one” in Italian) is investigating the safety and effectiveness of cannabidiol (or CBD oral solution) in infants (2 years of age and younger) with Tuberous Sclerosis Complex (TSC), Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) who experience inadequately controlled seizures.

TSC, LGS and DS are rare, early-onset epilepsies with life-long impact. Current treatment options for seizures associated with these conditions have substantial limitations, including poor seizure control and numerous side effects. Studies have shown that poor seizure control leads to additional health issues and a lower quality of life for those affected. Therefore, early treatment and control of seizures may be critical in improving the outcomes for children with these conditions.

For more information on the Jazz piccolo study please visit our website www.JazzPiccoloStudy.com

Or contact the nearest participating study site:

Site Specific Details to be Added Here
Principal Investigator:
Xxxxx Xxxxxx
Clinical Study Coordinator:
Xxxxx Xxxxxx
Telephone: +X XXX.XXX.XXXX
Email: xxxxx@xxxx.xxx

© 2024 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Here is a list of key Inclusion/Exclusion Criteria to participate in the study:

**KEY INCLUSION CRITERIA**
- Children with confirmed:
  - Tuberous Sclerosis Complex: 1 month to < 2 years of age; or
  - Dravet Syndrome: 1 year to < 2 years of age, or
  - Lennox-Gastaut Syndrome: 1 year to < 2 years of age
- Has seizures not adequately controlled through their current antiseizure medications
- Currently receiving 1 or more antiseizure medications
- A suitable Video EEG or VEEG for confirmation of diagnosis; VEEG is short for a video EEG (electroencephalograph) which records a patient’s experience on video while an EEG test records brainwave function

**KEY EXCLUSION CRITERIA**
- Clinically significant unstable medical condition other than epilepsy
- Clinically significant symptoms or illness which could affect the seizure frequency
- Has undergone surgery for epilepsy within 6 months
- Significantly impaired hepatic (liver) function
- Currently using recreational or medicinal cannabis, cannabinoid-based medications or CBD